<DOC>
	<DOCNO>NCT00281918</DOCNO>
	<brief_summary>This randomized phase III trial study fludarabine , cyclophosphamide , rituximab see well work compare fludarabine cyclophosphamide treat patient B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine Cyclophosphamide With Without Rituximab Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed Bcell chronic lymphocytic leukemia ( CLL ) define National Cancer Institute ( NCI ) Working Group criterion Meets 1 follow criterion : Binet stage C disease Binet stage B disease AND ≥ 1 follow sign symptoms* : B symptom ( night sweat , weight loss ≥ 10 % within previous 6 month , fever &gt; 38°C 100.4°F ≥ 2 week without evidence infection ) , constitutional symptom ( fatigue ) Continuous progression ( double peripheral lymphocyte count within past 6 month absolute lymphocyte count &gt; 50 G/I ) Evidence progressive marrow failure manifest development/worsening anemia and/or thrombocytopenia Massive , progressive painful splenomegaly hypersplenism Massive lymph node lymph node cluster ( &gt; 10 cm long diameter ) , danger organ complication large lymphoma ( e.g. , vascular compression tracheal narrow ) , progressive lymphadenopathy Occurrence symptomatic hyperviscosity problem leukocyte count &gt; 200 G/I ( symptomatic leukostasis ) NOTE : * Marked hypogammaglobulinemia development monoclonal protein absence criterion active disease sufficient eligibility No Binet stage A disease No transformation aggressive Bcell malignancy ( e.g. , diffuse large cell lymphoma , Richter 's syndrome , prolymphocytic leukemia ) PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Cumulative Illness Rating Scale ( CIRS ) score &gt; 6 Life expectancy &gt; 6 month Bilirubin ≤ 2 time upper limit normal ( ULN ) Alkaline phosphatase transaminases ≤ 2 time ULN Creatinine clearance ≥ 70 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study treatment No known hypersensitivity anaphylactic reaction humanize monoclonal antibody study drug No cerebral dysfunction precludes chemotherapy No active bacterial , viral , fungal infection No clinically significant autoimmune cytopenia Coombspositive hemolytic anemia No active malignancy require concurrent treatment except basal cell carcinoma tumor treat curatively surgery No medical psychological condition would preclude study therapy No concurrent disease require prolong ( &gt; 1 month ) therapy involve glucocorticoid PRIOR CONCURRENT THERAPY : No previous treatment CLL chemotherapy , radiotherapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>